BDX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

144.700

Open

142.020

VWAP

143.48

Vol

6.23M

Mkt Cap

39.67B

Low

141.745

Amount

894.13M

EV/EBITDA(TTM)

9.40

Total Shares

275.54M

EV

56.13B

EV/OCF(TTM)

14.39

P/S(TTM)

1.85

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

Show More

Events Timeline

(ET)

2026-05-07

16:30:00

Major Averages Close Lower, McDonald's Reports Growth

2026-05-07

12:00:00

Major Averages Little Changed as Oil Prices Decline Reflect Optimism

2026-05-07

09:00:00

Futures Rise on Declining Oil Prices

2026-05-07

07:00:00

Becton Dickinson Appoints Vitor Roque as CFO

2026-05-07

06:50:00

BD Reports Q2 Revenue of $4.71B, Exceeds Expectations

2026-05-07

06:50:00

Company Raises FY26 Revenue Outlook to Low Single-Digits

2026-05-06 (ET)

2026-05-06

15:00:00

McDonald's and Others Earnings Consensus Before Tomorrow's Open

News

CNBC

SpaceX Sets Record with $75 Billion IPO, Aiming for 25-30% Opening Pop

CNBC

Jim Cramer's Insights on Multiple Stocks

CNBC

Investment Recommendations for Zoetis and Energy Transfer

Fool

Analysis of Blue Chip Stock Investment Strategies

NASDAQ.COM

05-29NASDAQ.COM

Microsoft Shares Undervalued; Blue Chip Investment Opportunities

PRnewswire

05-21PRnewswire

BD Launches New Laser System to Enhance Urology Efficiency

11 Analyst Rating

Wall Street analysts forecast BDX stock price to rise

5 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

157.00

Averages

192.64

High

232.00

Current: 0.000

Low

157.00

Averages

192.64

High

232.00

BofA

Neutral

downgrade

$177 -> $170

AI Analysis

2026-06-12

Reason

BofA

Price Target

$177 -> $170

AI Analysis

2026-06-12

downgrade

Neutral

Reason

BofA lowered the firm's price target on Becton Dickinson to $170 from $177 and keeps a Neutral rating on the shares. Noting that the firm's services team continues to highlight a lower utilization environment, the analyst wants to take a more conservative view on 2027 medtech company estimates given valuations are already reflecting utilization risk, the analyst tells investors. The analyst, who is also assuming inflation is more of a headwind in 2027 with less margin expansion for medtech, lowers 2027 estimates across the firm's larger-cap coverage where there's exposure to utilization and inflation.

Barclays

NULL -> Overweight

maintain

$202 -> $204

2026-05-11

Reason

Barclays

Price Target

$202 -> $204

2026-05-11

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Becton Dickinson to $204 from $202 and keeps an Overweight rating on the shares post the fiscal Q2 report. Becton delivered solid operational growth and upside to consensus estimates, the analyst tells investors in a research note. The firm views the company as well positioned in the current macro environment.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 10.49, compared to its 5-year average forward P/E of 17.79. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

17.79

Current PE

10.49

Overvalued PE

21.42

Undervalued PE

14.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

14.52

Current EV/EBITDA

10.59

Overvalued EV/EBITDA

16.71

Undervalued EV/EBITDA

12.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.27

Current PS

1.98

Overvalued PS

3.83

Undervalued PS

2.71

Financials

AI Analysis

Annual

Quarterly

Whales Holding BDX

Cacti Asset Management, LLC

Deroy & Devereaux Private Investment Counsel, Inc.

Southpoint Capital Advisors LP

First Pacific Advisors, LP

Heartland Advisors, Inc.

American Century Investment Management

Trading Trends

People Also Watch

Frequently Asked Questions

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 143.98 USD — it has increased 1.67

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

What is the price predicton of BDX Stock?

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is192.64 USD with a low forecast of 157.00 USD and a high forecast of 232.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

Becton Dickinson and Co revenue for the last quarter amounts to 4.71B USD, increased 5.22

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

Becton Dickinson and Co. EPS for the last quarter amounts to -1.11 USD, decreased -203.74

How many employees does Becton Dickinson and Co (BDX). have?

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of June 20 2026.

What is Becton Dickinson and Co (BDX) market cap?

Today BDX has the market capitalization of 39.67B USD.